分子影像:時代的來到 是由出版商Espicom Business Intelligence在2011年08月所出版的。
這份英文市場調查報告書包含Pages: 290 價格從美金1740起跳。
本報告提供分子影像市場現況與趨勢，相關課題，到２０１５年為止的各部門市場預測，及加入此市場的主要75家公司的競爭簡介等彙整資料，為您概述為以下內容。
摘要整理
- 背景
- 目前市場趨勢
- 競爭環境
- SPECT市場近幾年的發展
- PET市場近幾年的發展
- 回本和相關法規在核可認証上的課題
- 市場預測
- 新興技術
- 學術機關所扮演的角色
- 合作開發的努力
- 新呈像方式
分子影像企業
- ABT Molecular Imaging
- ABX
- Advanced Accelerator Applications
- Advanced Cyclotron Systems
- Advanced Medical Isotope
- Affibody
- Agenix
- AntiCancer
- Aleres Pharmaceuticals
- Aposense
- ART Advanced Research Technologies
- Astellas
- AstraZeneca
- Atreus Pharmaceuticals
- Avid Radiopharmaceuticals (Eli Lilly)
- Bayer HealthCare Pharmaceuticals
- Bioscan
- Biospace Lab
- Bracco
- Bruker Biospin
- BV Cyclotron Vu
- Caliper Life Sciences
- Cardinal Health
- Carestream Health
- CellPoint
- Covidien
- Cyclopharma
- Digirad
- Dilon Diagnostics
- DRAXIMAGE
- Eckert & Ziegler
- Eczaciba_<BR>
i-Monrol Nuclear Products
- Erigal
- GE Healthcare
- Guerbet
- ?松Photonics
- IBA (Ion Beam Applications)
- Imaging Diagnostic Systems
- ImaginAB
- Immunomedics
- INDEC Systems
- IntraMedical Imaging
- Kereos
- Lantheus Medical Imaging
- Lightools Research
- Mediso Medical Imaging Systems
- MiLabs
- Molecular Insight Pharmaceuticals
- Naviscan
- Neoprobe
- Neurologica
- Nordion
- Novelos Therapeutics (Cellectar)
- NuView Life Sciences
- OncoVision
- PerkinElmer
- Pharmalucence
- Philips Healthcare
- Positron
- Proportional Technologies
- Scintomics
- Seno Medical Instruments
- 島津醫學Systems
- Siemens Healthcare
- Sofie Biosciences
- Spectrum Dynamics
- Triad Isotopes
- UltraSPECT
- United Pharmacy Partners
- Visualsonics (Sonosite)
- Wilex
圖表
Abstract
- Critical review of the market conditions, trends and challenges
- Unique market forecasts to 2015 by major sector
- Comprehensive and detailed competitive analysis of 75 leading players
The early vision for molecular imaging (MI) was that it would revolutionise
clinical diagnostics and pharmaceutical research, allowing disease to be
explored and identified with greater accuracy and long before physical
symptoms were experienced. But economic recession and technical challenges
have taken their toll on the speed at which that vision has become reality -
until now. While for many years MI delivered more promise than profits, the
signs are that new products, applications and increasing clinical/health payer
acceptance will see the market accelerate in the medium term to achieve global
sales of US$6 billion by 2015.
Strong fundamentals are driving growth
Despite cost pressures from reduced capital spending and lower reimbursement
for some procedures, the MI market fundamentals remain solid and there are
strong opportunities for growth within the MI industry. The increasing
incidence of cancer, cardiovascular and neurological diseases means that
demand for faster and more accurate diagnosis, as well as drug development and
pre-clinical study efforts, will continue to accelerate in the coming years.
In addition, imaging technologies will become more widely adopted as clinical
evidence is established as to their benefits, and new technological
innovations continue to be brought to market, particularly related to the MI
of cancer and neurological diseases. In addition, the current lack of
penetration for nuclear and molecular imaging in emerging economies such as
China, India and Brazil is driving demand in these regions, where new nuclear
imaging facilities are being set up and lower-cost systems are in demand.
Corporate manoeuvres
The industry is still developing but already companies in the medical
diagnostic imaging equipment business such as Philips, Siemens and GE, and in
the radiopharmaceutical and contrast agent market such as GE, Bracco,
Covidien, Bayer and Lantheus Medical Imaging are taking leading positions. And
opportunities for big Pharma are not being missed, with both Eli Lilly and
AstraZeneca actively involved. As the market develops, expect more
consolidation in the tussle for dominance.
This new report provides unique 5-year market forecasts
Molecular imaging is still a developing sector and the question is often asked
what it will be worth commercially. For the first time, this report provides a
5-year evaluation of the market' s prospects and provides year-by year growth
for key sectors:
- Nuclear Imaging
- Pre-Clinical Imaging Systems
- Molecular Imaging End-Use Products Market
- Radiopharmaceuticals
This report easily answers key business questions such as:
- Which sector of the molecular imaging market is expected to achieve global
sales of US$3.5 billion in 2015?
- What steps are being taken to ensure availability of the key istope Mo-99?
- How is Gallium-68 being used to better understand cancer cell migration?
- What advantages does PET have over other imaging technologies?
- What challenges must be overcome to meet growing demand in emerging
markets and how is this influencing developers?
- Which European company is developing nanoprobes which identify the
expression of the HER2 protein and with whom is it collaborating?
- Which US company was granted a European patent in March 2011 for its
contrast agent used in the diagnosis of deep vein thrombosis?
- Now approved in the US and EU, does Digirad' s portable nuclear system mark
a move to distributed MI technologies?
- Only one company offers a full suite of MI products - is this a
competitive advantage and does it represent an opportunity for further
entrants to provide whole-market service?
A complete analysis packed with market analysis, sector forecasts to 2015 and detailed company evaluations
Trends and challenges - make sure you are fully briefed on the issues which are shaping the market...
Are the cost benefits of molecular imaging being recognised?
Health payers, in the midst of an economic downturn, are focused on limiting
immediate costs and this has impacted expansion and reimbursement of several
imaging procedures. But advanced imaging enables detection and diagnosis at
earlier stages of disease development, enabling treatment to begin before
disease becomes systemic or established and reducing costs for invasive
surgery or later-stage drug treatments. Similarly, there is much concern over
the cost of new drugs, many of which may be used without the most accurate
diagnostic insight into the underlying pathology of the disease. Molecular
imaging' s advanced ability to evaluate disease at the molecular level has a
critical role to ensure that only appropriate medicines are administered.
Evidence is still building, but health payers would be wise to consider future
molecular imaging technology as a benefit and not a cost in their financial
plans.
Molecular Imaging - only for the big boys?
Although MI technologies hold great promise and market potential, there are
significant barriers to market entry for companies, including the significant
capital investments required to develop such products and get them through the
lengthy and costly regulatory approval process. Adding to the challenge has
been the difficult economic environment in recent years, which has limited the
ability of start-up companies to raise capital from financial institutions or
attract investment. Despite a difficult market for start-ups, the strong
growth potential of MI technologies is providing good opportunities for
companies with cash or financing available to them to add to their MI
operations or enter this market, both through acquisitions or by licensing
technologies from companies that cannot afford to commercialise them
themselves.
A case in point...
Alzheimer' s disease imaging is currently a major area of opportunity, both in
terms of helping to achieve a clinical diagnosis for a condition that can
currently only be diagnosed at autopsy and also for pharmaceutical companies
developing drugs to treat the condition. Previously privately-held, Avid
Radiopharmaceuticals was acquired by the multi-national pharmaceutical
company, Eli Lilly and Company, in December 2010. Avid' s lead MI agent,
Amyvid, is being developed to diagnose Alzheimer' s disease and is expected to
become the first MI agent for Alzheimer' s disease to be FDA-approved later in
2011. There are plenty of examples where smaller companies have ceased trading
or changed status - investment capital is crucial to innovation, and how much
of that comes from big Pharma will be closely watched.
In research...new imaging modalities
MI is driven by technical innovation. New modalities in research include GMI' s
dual modality MRI/SPECT system, Philip' s Magnetic Particle Imaging platform
for imaging nanoparticle concentrations in blood and GE' s 13C Hyperpolarised
metabolic MR, which produces real-time, quantitative data regarding the
presence and aggressiveness of tumours.
About the Author
This report has been researched and written by senior Espicom medical market
analyst Joanne Maddox. For over 10 years she has played a pivotal role in
tracking trends in medical device and equipment markets and companies. A
former editor of Medical Device Companies Analysis she has also written
Medical IT: Understanding the major players and products, All Change in the
Advanced Woundcare Market and Point of Care Diagnostics: Players, Products and
Prospects.
Table of Contents
EXECUTIVE SUMMARY
BACKGROUND
- Applications of MI
- Neurological Disease
- Oncology
- Cardiovascular Disease
- MI for Drug Development
- MI Modalities
- Hybrid MRI/PET Imaging
- Tracers and Radiopharmaceuticals
CURRENT MARKET DYNAMICS
- Fig.1: Diagnostic Imaging Systems Market by Modality, 2010
- Fig.2: Medical Imaging Market, 2005-2010 (US$ billion)*
- Fig.3: Nuclear Imaging Equipment Market, 2007-2010 (US$ billion)*
- Fig.4: Molecular Imaging Market by End-Use Product Type, 2010
- Competitive Landscape
- Barriers to Market Entry and Market Consolidation
- Recent Developments in the SPECT Market
- Molybdenum-99 Isotope Supply Issues
- New Supply Initiatives
- Alternative Tc-99m Production Methods
- Recent Developments in the PET Market
- Alzheimer' s Disease PET Imaging
- National Institute on Aging/Alzheimer' s Association Diagnostic
Guidelines for Alzheimer' s Disease
- Products in Development
- Reimbursement and Regulatory Approval Issues
MARKET OUTLOOK
- Molecular Imaging: Market Drivers, Restraints & Future Opportunities
- Fig.5: Nuclear Imaging Equipment Market, 2010-2015E (US$ million)*
- Fig.6: Pre-Clinical Imaging Systems Market, 2010-2015E (US$ million)
- Fig.7: Radiopharmaceuticals Market, 2010-2015E (US$ million)
- Fig.8: Molecular Imaging End-Use Products Market, 2010-2015E (US$
million)*
- Emerging Technologies
- The Role of Academic Institutions
- Collaborative Development Efforts
- New Imaging Modalities
- MRI/SPECT
- Philips' Magnetic Particle Imaging
- GE Healthcare and 13C Hyperpolarised Metabolic MR
MOLECULAR IMAGING COMPANIES
ABT MOLECULAR IMAGING
ABX
ADVANCED ACCELERATOR APPLICATIONS
- Recent Events
- Products
- Current Alliances
- Institut Curie
- IASON GmbH
- European Molecular Imaging Manufacturers Association
- Bracco
- Financial Performance
- Fig.9: Advanced Accelerator Applications - Sales by Segment, 2010
ADVANCED CYCLOTRON SYSTEMS
- Recent Events
- Products
- TR 24 Cyclotrons
- TR 30 Cyclotrons
- TR PET Cyclotrons
- R&D Programme: Cyclotron Production of Tc-99m in Canada
- Current Alliances
ADVANCED MEDICAL ISOTOPE CORPORATION
- Products in Development
- US Production of Molybdenum-99
- Financial Performance
- AMIC - Operating Results, 2006-2010 (US$ thousand)
- Latest Results
AFFIBODY
- MI Research Studies
- Alliance with GE Healthcare
AGENIX
ALSERES PHARMACEUTICALS
- Altropane
- Altropane for Dementia with Lewy Bodies
ANTICANCER
- Research and Development
- Gene-Based Fluorescence-Labelling Technology for Cancer Surgery
- Current Alliances
- UVP
- Caliper Life Sciences
- INDEC Systems
- Olympus
APOSENSE
- [18F]-ML-10 and EarliTest
- Current Agreements
- University of Pittsburgh
- Roche
- IBA
- GlaxoSmithKline
- Sigma-Aldrich
ART ADVANCED RESEARCH TECHNOLOGIES
- ART: Recent Events
- Products
- Optix MX3
- SoftScan Optical Breast Imaging System
- Clinical Trial Results
- Fenestra Contrast Agents
ASTELLAS PHARMA
- Lexiscan (regadenoson)
- Adenoscan (adenosine injection)
- Cardiac Imaging Revenue
- Fig.10: Astella Pharma Cardiac Imaging Sales, Fiscal 2008-2010 (US$
million)
ASTRAZENECA
- [11C]AZD2184
- [18F]-AZD4694
ATREUS PHARMACEUTICALS
- Alliance with Advanced Proteome Therapeutics
AVID RADIOPHARMACEUTICALS (ELI LILLY)
- Amyvid (florbetapir F 18 injection)
- 18F-AV-133
- Current Alliances
PETNET Solutions (Siemens Healthcare)
- Adler Institute for Advanced Imaging
- Bayer HealthCare Pharmaceuticals
BAYER HEALTHCARE PHARMACEUTICALS
- Recent Key Events
- Research and Development
- Florbetaben PET Tracer
- BAY 86-4367 for Prostate Cancer PET Imaging
- BAY 94-9392 for Tumour Imaging
- Current Alliances
- Ion Bean Applications
- AC Immune
- Celera (Quest Diagnostics)
- Hamamatsu Photonics
- Nagasaki University
- FutureChem
- Avid Radiopharmaceuticals (Eli Lilly)
- Taisho Pharmaceutical, Nihon Nohyaku and National Institute of
Radiological Sciences, Japan
- Stanford University
- Philips
- Magnetic Particle Imaging Technology Consortium
- MEDITRANS
BIOSCAN
- NanoSPECT/CT and NanoPET/CT
- NanoSPECT/CT and NanoSPECT/CTPlus
- NanoPET/CT
- HiSPECT
- In Development - Pre-clinical PET/MRI System
BIOSPACE LAB
- Recent Key Events
- Products
- Photon Imager System
- Gamma Imager
- Beta Imager
- Micro Imager
- Beta Microprobe
- M3 Vision Software
- Current Alliances
- LabChina Co Ltd and LabChina Taiwan Co Ltd
- Promega France
BRACCO
- Products
- Research and Development
- Current Alliances
- Advanced Accelerator Applications (AAA)
- ImaRx Therapeutics
- VisualSonics
- MEDITRANS
BRUKER BIOSPIN
- Recent Key Events
- Products
- BioSpec Pre-Clinical MRI
- BioSpec 150/11
- BioSpec 117/16
- Icon
- ClinScan
- PharmaScan
- MRI CryoProbe
- ParaVision 5.0 Software
- Current Alliances
- Philips
- Magnetic Particle Imaging Technology Consortium
- Aspect Imaging
- University of York, UK
- Iseult Programme
- BioSpec 170/25
- Siemens
BV CYCLOTRON VU
- Alliance with IBA Group
- Alliance with VU University Medical Centre
CALIPER LIFE SCIENCES
- Recent Key Events
- Pre-Clinical Imaging Products
- IVIS Imaging Systems
- Living Image 4.0 Software
- Reagents and Accessories
- Quantum FX MicroCT System
- Living Image Multi Modality Software Module and the Mouse Imaging Shuttle
- Maestro MI Systems
- Maestro Dynamic
- Maestro EX
- Maestro 2
- Current Alliances
- VisEn Medical (PerkinElmer)
- DuPont
- AntiCancer
- Invitrogen
- Stanford University
- Massachusetts General Hospital
- Litigation with Carestream Health
- Financial Performance
- Fig.11: Caliper Life Sciences - Revenue by Division, 2010
- Latest Results
- Outlook
CARDINAL HEALTH
- Recent Key Events
- Products
- Current Alliances and Collaborations
- ProVision Healthcare
- University of Washington
- American College of Radiology Imaging Network
- Ohio Third Frontier and Ohio State University
- IBA Group
- Eckert & Ziegler
- GE Healthcare
- Syntermed
- Neoprobe
- Lantheus Medical Imaging
CARESTREAM HEALTH
- Albira PET/SPECT/CT System
- In Vivo Imaging Solutions
- In-Vivo MS FX PRO
- In-Vivo FX Pro
- In-Vivo F PRO
- In-Vivo Imaging System FX
- In-Vivo DXS PRO
- Carestream Molecular Imaging Software
- Litigation with Caliper Life Sciences
CELLPOINT
- EC Technology
- 99mTc-EC-G for Oncology
- 99mTc-EC-Metronidazole for Stroke
- Tumour Hypoxia
- N4 Technology
- Dual Agent Technology
- Beta Cell Technology
- Current Alliances
- Eli Lilly and Company
- Philips Healthcare
- M D Anderson Cancer Center
COVIDIEN
- Fig.12: Covidien' s Imaging Sales, 2006-2010 (US$ million)
- Radiopharmaceuticals
- Current Alliances
- Positron
- Institute of Atomic Energy, Poland
- Babcock & Wilcox
- Siemens
- BV Cyclotron VU
CYCLOPHARMA
DIGIRAD
- Recent Key Events
- Products
- ergo
- Cardius XPO Series
- Cardius X-ACT
- c.pax
- Alliance with Dilon Diagnostics
- Financial Performance
- Digirad - Operating Results, 2006-2010 (US$ million)
- Fig.13: Digirad - Revenue by Division, 2010
- Latest Results
DILON DIAGNOSTICS
- Recent Key Events
- Dilon 6800 Gamma Camera
- Dilon 6800 Acella
- GammaLoc
- Recent BSGI Clinical Trial Results
- Current Alliances and Contracts
- Digirad
- Philips
- Terason Ultrasound
- PenRad Mammography Information Systems
DRAXIMAGE
- Products
- Current Alliances
ECKERT & ZIEGLER
- Recent Key Events
- Products and Services
- Bioscan Analytical and Radiochemistry Products
- Contracts and Alliances
- Euromedic International
- ZAG Zyklotron
- Polish Medical University of Gdansk
- Cardinal Health
- Financial Performance
- Eckert & Ziegler Operating Results, 2007-2010 (EUR million)
- Fig.14: Eckert & Ziegler - Revenue by Product Segment, 2010
- Latest Results and Outlook
ECZACIBASI-MONROL NUCLEAR PRODUCTS
ERIGAL
EUSA PHARMA
FLUOROPHARMA MEDICAL
- Product Pipeline
- CardioPET
- BFPET
- VasoPET
- AZPET
GAMMA MEDICA-IDEAS
- LumaGEM Molecular Breast Imaging System
- Triumph Pre-Clinical Imaging
- Research and Development
- Current Alliances
- Mayo Clinic
- GE Healthcare
- SII NanoTechnology
- Exxim Computing
GE HEALTHCARE
- Recent Key Events
- Products
- PET/CT +MR Imaging Platform
- Nuclear Medicine
- Discovery NM630 SPECT System
- Alcyone Technology SPECT/CT Products
- Infinia Hawkeye SPECT/CT
- Millennium and Infinia General Purpose Systems
- Ventri Cardiology System
- PET/CT
- Optima PET/CT 560
- Discovery PET/CT
- Pre-Clinical Systems
- Triumph II
- GE eXplore CT 120
- eXplore speCZT
- eXplore Locus SP
- eXplore Locus
- LabPET Solo
- PET Radiopharmacy Products
- Nuclear and Molecular Imaging Agents
- AdreView (Iobenguane I 123) Injection
- DaTscan (Ioflupane I 123 Injection)
- Myoview
- Ceretec
- DRYTEC
- Hexvix/Cysview
- Research and Development
- Research Projects
- MI Agents
- 13C Hyperpolarised Metabolic MR
- Fluorescent Imaging
- Research Collaborations
- ImaginAb
- The Medical College of Wisconsin
- Immunomedics
- Brigham and Women' s Hospital
- Gamma Medica-Ideas
- University of Pittsburgh
- PredictAD Project
- Merck & Co
- Fraunhofer Institut fur Toxikologie und Experimentelle Medizin
- University of Washington
- Affibody
- Roche
- University of Illinois at Chicago
- Distribution and Other Agreements
- Rapidscan Pharma Solutions
- Advanced Cyclotron Systems Inc
- Neuroimage
- Joint Venture with Nycomed
- Nihon Medi-Physics Joint Venture with Sumitomo Chemical
- Photocure
- IntraMedical Imaging
- Lantheus Medical Imaging
- Financial Performance
- GE Healthcare Operating Results, 2005-2010 (US$ million)
- Fig.15: GE Healthcare - Revenue by Product, 2010*
GUERBET
- Research and Development
- Current Alliances and Collaborations
- Gallimed Project - Nordion and Cyceron
- IMAkinib
- DRAXIMAGE
- Iseult Programme
- MediTrans
HAMAMATSU PHOTONICS
- Products
- Animal PET Scanner SHR-7700
- Research and Development
- Reflectance Diffuse Optical Tomography
- Alliances
- Bayer HealthCare Pharmaceuticals
IBA (ION BEAM APPLICATIONS)
- Recent Key Events
- MI Products and Services
- Radiopharmaceuticals
- New Product Approvals
- Cyclotron Equipment
- Research and Development
- Current Alliances and Contracts
- KeyMarker Consortium
- Servicio Andaluz de Salud, Spain
- Dehnel - Particle Accelerator Components and Engineering
- CEA, France, and IRE, Belgium
- Bayer HealthCare Pharmaceuticals
- Bio Molecular Industries
- SISORA
- Aposense
- Eczacibasi-Monrol Nuclear Products
- BV Cyclotron VU
- Hae Dong Co Ltd
- Lantheus Medical Imaging
- Wilex
- Financial Performance
- IBA - Operating Results, 2006-2010 (EUR million)
- IBA - Revenue by Business Unit, 2006-2010 (EUR million)
- Fig.16: IBA - Revenue by Business Unit, 2010
- Latest Results
IMAGINAB
- Recent Key Events
- Research Projects
- Current Alliances
- GE Imanet
- Oxford BioMedica
- KeyMarker Consortium
- University of California, Los Angeles
- Dainippon Seiki
- Singapore' s Agency for Science, Technology and Research
- GlaxoSmithKline
- BZL Biologics
IMAGING DIAGNOSTIC SYSTEMS
- CTLM System
- Fluorescence and Molecular Imaging
- Laser Imager for Lab Animals (LILA)
- Financial Performance
- IDSI - Operating Results, 2006-2010 (US$)
- Latest Results
IMMUNOMEDICS
- LeukoScan
- Research and Development
- TF2 for Colorectal Cancer Imaging and Radioimmunotherapy
- Peptides for Imaging
- Current Alliances
INDEC SYSTEMS
INTRAMEDICAL IMAGING
- KEREOS
- Product Pipeline
- KI-0001
- KI-0003
- R&D Collaborations
- Washington University
- The Dow Chemical Company
LANTHEUS MEDICAL IMAGING
- Recent Key Events
- Products
- ABLAVAR (Gadofosveset Trisodium)
- Cardiolite
- TechneLite (Technetium Tc99m Generator)
- Research and Development
- Flurpiridaz F 18
- LMI 1195 for Cardiac PET Imaging
- BMS 753951
- Current Alliances and Contracts
- Nordion
- Novation
- NTP Radioisotopes
- Amerinet
- Institute for Radioelements, Belgium, and Nuclear Research Institute,
Czech Republic...
- Cardiolite and TechneLite Distribution Agreements
- Australian Nuclear Science and Technology Organisation
- IBA Group
- Financial Performance
- Lantheus Medical Imaging - Operating Results, 2007-2010 (US$ million)
- Lantheus Medical Imaging - Sales by Key Product Line, 2008-2010 (US$
million)
- Fig.17: Lantheus Medical Imaging - Revenue by Product Line, 2010
- Lantheus Medical Imaging - Sales by Region, 2008-2010 (US$ million)
- Fig.18: Lantheus Medical Imaging - Sales by Region, 2010
- Latest Results
LIGHTOOLS RESEARCH
- MI Products
- Pan-A-See-Ya Panorama
- Macro-Illumination Imaging System
- Macro-Imaging System Plus
MEDISO MEDICAL IMAGING SYSTEMS
- AnyScan SPECT-CT-PET
- Nucline Gamma Cameras
- Pre-Clinical PET/MRI Collaboration with Aspect Imaging
MILABS
- Products
- VECTor
- U-SPECT-II/CT
- U-CT
- U-SPECT II Scanners
- Current Alliances
- SkyScan
- Mid-Atlantic Imaging Services
MOLECULAR INSIGHT PHARMACEUTICALS
- Recent Key Events
- Research and Development
- Zemiva
- Trofex
- Trofex for Treatment Monitoring
- Hypoxia Imaging Radiopharmaceuticals
- Tc-99m-Labelled Peptide for Targeting Neuroendocrine Tumours
- Current Alliances
- Recent Key Events
- Positron Emission Mammography Scanner
- PEM Clinical Study Results
- Stereo Navigator
- MIMviewer PEM
- Current Alliances
- Chindex Medical
- Tecnologie Avanzate
- Neoprobe
- Nuclear Medicine Distributors
- SCETI
- Hae Dong Co Ltd
- MIMVista
NEOPROBE
- Recent Key Events
- Gamma Detection Products
- Research and Development
- Lymphoseek
- Breast Cancer and Melanoma
- Head and Neck Squamous Cell Carcinoma
- RIGScan CR
- Current Alliances and Licences
- Naviscan
- Dow Chemical Company
- Laureate Pharma
- Cardinal Health
- University of California, San Diego
- Financial Performance
NEUROLOGICA
NORDION
- Recent Key Events
- Products
- Medical Isotopes
- Medical Isotope Supply Issues
- Current Alliances
- Lantheus Medical Imaging
- The Open Joint Stock Company "Isotope"
- Gallimed Project - Guerbet and Cyceron
- Bracco
- TRIUMF and the University of British Columbia
- University of Ottawa Heart Institute
- Molecular Insight Pharmaceuticals
- Financial Performance
- Nordion - Results from Continuing Operations, 2008-2010 (US$ million)
- Fig.19: Nordion - Revenue by Segment, 2010
- Nordion - Sales and Earning by Segment, 2008-2010 (US$ million)
- Medical Isotope Segment Results
- Fig.20: Nordion: Medical Isotope Sales and Earnings, 2008-2010 (US$
million)
- Latest Results
NOVELOS THERAPEUTICS (CELLECTAR)
NUVIEW LIFE SCIENCES
- Alliance with Thomas Jefferson University - VPAC1 For Imaging Prostate
Cancer
- NVB64-PET for Breast Cancer Diagnosis
ONCOVISION
- Albira PET/SPECT/CT System
- Mammi Breast PET Imaging System
PERKINELMER
- Recent Key Events
- Fluorescence Molecular Tomography Imaging Systems
- Multispecies Imaging Module
- Imaging Agents
- Current Alliances
- MosaMedix
- Cambridge Research & Instrumentation (Caliper Life Sciences)
- Merck
PHARMALUCENCE
PHILIPS HEALTHCARE
- Recent Key Events
- Nuclear Medicine Products
- Ingenuity TF PET/MR
- PET/CT
- TruFlight Select PET/CT
- Ingenuity TF PET/CT
- Gemini PET/CT
- SPECT/CT Systems
- BrightView XCT
- BrightView X
- BrightView SPECT
- Precedence SPECT/CT
- SKYLight
- CardioMD
- Dilon Diagnostics' Dilon 6800 Gamma Camera
- IntelliSpace Portal
- Extended Brilliance Workspace
- JETStream Workplace
- Pre-Clinical Imaging
- Research and Development
- Research Establishments
- High Tech Campus
- Molecular Imaging R&D Projects
- Magnetic Particle Imaging
- Medical Optical Imaging
- Research Alliances
- Eindhoven University of Technology & the Sonodrugs Project
- University of Washington Medical Center
- VU University Medical Center
- Bruker BioSpin
- Bayer HealthCare Pharmaceuticals
- CellPoint
- Distribution and Licensing Agreements
ROSATOM
- Dilon Diagnostics
- Bioscan
- Sun MicroSystems
- Financial Performance
- Philips Healthcare: Operating Results, 2007-2010 (EUR million)
- Fig.21: Philips Healthcare - Revenue by Segment, 2010
- Fig.22: Philips Healthcare - Revenue by Region, 2010
POSITRON
- Recent Key Events
- Products
- PosiRx
- Attrius Cardiac PET Scanner
- Tech-Assist
- Radiopharmaceuticals
- Current Alliances
- Covidien
- Technology Imaging Services
- MedAxiom
- Financial Performance
- Positron - Operating Results, 2006-2010 (US$ thousand)
- Latest Results
PROPORTIONAL TECHNOLOGIES
- Cu-62 Micro-generator
- Products in Development
- PET Camera for Breast Imaging
- PET Camera for Small Animal Studies
- SCINTOMICS
- Products
- Hotbox-III (HB-III)
- GallElut
- GRP Modules
- µ-ICR
- InViala
- In Development
SENO MEDICAL INSTRUMENTS
SHIMADZU
- MI Products
- PET Systems
- PET/CT Systems
- Clairvivo Pre-Clinical PET System
- Research Agreement with the National Cancer Center, Tokyo, Japan
SIEMENS HEALTHCARE
- Recent Key Events
- Molecular Imaging and PET Products
- Biograph mMR MRI-PET System
- PET/CT
- Biograph mCT 20 Excel
- Biograph mCT
- Biograph TruePoint PET/CT
- syngo Dynamic PET with Myocardial Blood Flow
- SPECT and SPECT/CT Systems
- Symbia TruePoint SPECT/CT Systems
- SPECT Systems
- Symbia.net
- MI Workstations and Software
- syngo.via
- syngo MI Workplace
- Pre-Clinical Imaging
- Inveon
- microPET Focus 220
- Biomarkers
- Explora Radiochemistry Modules
- Eclipse Cyclotrons
- PETNET Solutions' PET Radiotracers
- R&D Activities
- Siemens Molecular Imaging Biomarker Research
- [18F]-SMIBR-W372 Biomarker
- CA-IX Biomarker
- HX4 Biomarker
- Research Agreements
- University of Texas M D Anderson Cancer Center
- Iseult Programme and Commissariat a l' Energie Atomique
- Massachusetts General Hospital
- Supply, Distribution and Licensing Agreements
- Avid Radiopharmaceuticals (Eli Lilly)
- Lantheus Medical Imaging
- Covidien
- Medical University of South Carolina
- Cleveland Clinic
- Bruker BioSpin
- University of Muenster
- Financial Performance
- Siemens Healthcare - Operating Results, 2006-2010 (EUR million)
- Siemens Healthcare - Imaging and IT Division Results, 2006-2010 (EUR
million)
- Fig.23: Siemens Healthcare Sales by Division, 2010
- Latest Results
SOFIE BIOSCIENCES
ELIXYS
SPECTRUM DYNAMICS
- D-SPECT Cardiac Imaging System
TRIAD ISOTOPES
ULTRASPECT
UNITED PHARMACY PARTNERS
VISUALSONICS (SONOSITE)
- Recent Key Events
- Products
- Vevo LAZR Photoacoustic Imaging System
- Vevo 2100
- Vevo 770
- Vevo SoniGene
- MicroMarker Contrast Agent Kits
- Mauna Kea Technologies' Pre-Clinical Imaging Technologies
- Cellvizio LAB
- NeuroPak Deep Brain Imaging System
- Current Alliances
- Mauna Kea Technologies
- Seno Medical Instruments
- Bracco
- University of Virginia
WILEX
- Redectane
- Alliance with IBA Group
APPENDICES
APPENDIX 1 - LIST OF ABBREVIATIONS
APPENDIX 2 - REPORT METHODOLOGY
|
